Vimarsana
Biggest News Aggregation in the World

Odronextamab Clinical Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Odronextamab Clinical Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Odronextamab Clinical Program Today - Breaking & Trending Today

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes - Vimarsana News

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

Published: December 10, 2023

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate , with 31% achieving a complete response Results from a Phase 1 expansion cohort showed a...

Source: marketscreener.com
Related Topics:
United StatesSan DiegoJone ArnasonVesna TosicSabarish Ram AyyappanTammy AllenDrug AdministrationInternational Prognosis IndexRegeneron Genetics CenterRegeneron Pharmaceuticals IncOdronextamab Clinical ProgramGlobenewswire IncAmerican Society Of HematologyEuropean UnionEuropean Medicines AgencyExchange CommissionBeth Israel Deaconess Medical CenterAnnual MeetingHope AtlantaIsrael Deaconess Medical CenterMedicines AgencyFast Track DesignationOrphan Drug DesignationOdronextamab ClinicalLugano Classification
Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes - Vimarsana News

Updated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes

Published: December 10, 2023

Phase 2 primary analysis results presented in ASH oral session demonstrated a 52% objective response rate , with 31% achieving a complete response Results from a Phase 1 expansion cohort showed a...

Source: marketscreener.com
Related Topics:
United StatesSan DiegoSabarish Ram AyyappanJone ArnasonTammy AllenVesna TosicBeth Israel Deaconess Medical CenterOdronextamab Clinical ProgramInternational Prognosis IndexAmerican Society Of HematologyRegeneron Pharmaceuticals IncEuropean UnionDrug AdministrationExchange CommissionRegeneron Genetics CenterEuropean Medicines AgencyAmerican SocietyAnnual MeetingHope AtlantaFast Track DesignationOrphan Drug DesignationOdronextamab ClinicalLugano ClassificationDiffuse Largeb Cell LymphomaRegeneron Genetics
Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review - Vimarsana News

Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review

Published: September 29, 2023

If approved, odronextamab would be the first and only bispecific antibody approved in both FL and DLBCL – the two most common subtypes of non-Hodgkin lymphoma European Medicines Agency also...

Source: marketscreener.com
Related Topics:
United StatesVesna TosicTammy AllenAmerican Society Of Hematology Annual MeetingRegeneron Pharmaceuticals IncEuropean Medicines AgencyDrug AdministrationExchange CommissionOdronextamab Clinical ProgramRegeneron Genetics CenterRegeneron Approach To Cancer ResearchMedicines AgencyMarketing AuthorizationPriority ReviewBiologics License ApplicationAmerican SocietyHematology AnnualOrphan Drug DesignationFast Track DesignationMarketing Authorization ApplicationOdronextamab ClinicalLugano ClassificationRegeneron GeneticsLooking StatementsRegeneron Pharmaceuticals